Skip to main content

Featured

The CUSMA Countdown: 24 Days to a Trade Deadline That Could Hit Your Wallet

Canada's free trade deal with the U.S. hits a mandatory review milestone on July 1. With negotiations unresolved and Washington demanding changes, here's what it actually means for your groceries, your car, and your job. MoneySavings.ca Staff Canadian Money Brief June 7, 2026 5 min read What Is CUSMA and Why Does July 1 Matter? CUSMA — the Canada-United States-Mexico Agreement — is the trade deal that keeps the North American economy humming. It replaced NAFTA in 2020 and governs the movement of trillions of dollars in goods and services across the Canada-U.S. border every year. For Canadian consumers, it's largely invisible — until it isn't. Built into the agreement is a mandatory six-year joint review, and that clock expires on July 1, 2026 . By that date, all three countries must declare whether they want to renew the deal for another 16 years, trigger annual reviews, or walk away. Whatever they decide, CUSMA technically stays in force until 2036 — but the path chose...
Post a Comment
Read more

article

Labels

U.S. Drug Tariffs: A Looming Crisis for Global Supply Chains


The U.S. government's decision to impose tariffs on pharmaceutical imports has sent shockwaves through the healthcare industry, raising concerns about potential drug shortages and skyrocketing costs. Industry leaders warn that these tariffs could disrupt critical supply chains, affecting the availability of essential medications and medical devices.

Johnson & Johnson CEO Joaquin Duato has voiced concerns over the impact of these tariffs, advocating for tax incentives instead of trade barriers to support domestic drug manufacturing Warns Tariffs Could Disrupt U.S. Drug Supply Chains](https://www.theglobeandmail.com/investing/markets/stocks/LLY-N/pressreleases/31903548/jj-ceo-jnj-warns-tariffs-could-disrupt-us-drug-supply-chains/). Meanwhile, a recent survey indicates that healthcare executives anticipate significant price hikes, with some predicting an 18% increase in medical equipment costs and a 33% rise in critical device prices.

The American Hospital Association has urged the administration to reconsider these tariffs, emphasizing the reliance of U.S. healthcare providers on international sources for life-saving drugs and supplies. Experts caution that while the tariffs aim to boost domestic production, the transition could take years, leaving patients vulnerable to shortages and inflated prices.

As pharmaceutical companies scramble to adjust their supply chains, the industry faces an uncertain future. Whether these tariffs will achieve their intended goal or exacerbate existing challenges remains to be seen. Policymakers must weigh the long-term consequences carefully to ensure that patient care and affordability are not compromised.

Labels:

Comments

Post a Comment